ANSWERS TO YOUR MOST PRESSING QUESTIONS
FAQs
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.2
EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified
healthcare professional.
EUFLEXXA works in 2 ways to keep you moving forward.2-5
Lubricates & Cushions2-4
Reduces Inflammation & Pain2-5
Helps produce natural HA found in the body
It does! In fact, EUFLEXXA is the HA injection that most closely resembles the natural, healthy HA in your knee.2,6-11
In a 12-week clinical trial*:
Patients treated with EUFLEXXA experienced powerful pain relief† as early as 1-week after the first injection, which continued to improve after each one.2,12
at the end of the 12-week study12
Pain-free is defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20mm).
*Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.
†Based on % reduction in Western Ontario and McMaster Universities Osteoarthritis Index pain score from baseline in a pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158). Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = 101/160.
Pain relief can begin as early as a week after your first injection and continues to improve after each injection for up to 6 months.2,12
The most common adverse reactions reported in a clinical trial of EUFLEXXA were joint pain, back pain, limb pain, muscle pain, and joint swelling.2
EUFLEXXA is 3 injections given into the knee joint by your doctor. Each injection should be given 1 week apart.2
EUFLEXXA is the HA injection that most closely resembles the natural, healthy HA in your knee.
By working in 2 ways, it helps lubricate and cushion your knee while reducing inflammation and pain.2-11
In fact, a 12-week clinical trial* showed that patients treated with EUFLEXXA experienced pain relief† after the first injection, which continued to improve after each one. Nearly 2/3 of EUFLEXXA patients were PAIN-FREE at the end of the 12-week study.2,12
Pain-free is defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20mm).
See what you can expect by watching a real patient’s experience with EUFLEXXA.
*Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.
†Based on % reduction in Western Ontario and McMaster Universities Osteoarthritis Index pain score from baseline in a pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158). Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = 101/160.
Yes. Repeat treatment with EUFLEXXA was proven well-tolerated for an additional 6 months. That’s why it’s important to stay ahead of the pain and follow-up with your doctor 6 months after your third injection to schedule another course of EUFLEXXA.2,13,14
Yes. Ask your doctor what will work best for you.2
While injection pain is individual, your doctor may discuss options to numb your knee before EUFLEXXA is given to offset any potential discomfort.
It’s important to follow these 3 steps2:
Avoid physical activity for 48 hours, including standing for more than 1 hour at a time
Ice your knee if you have any mild pain or swelling
If you experience joint pain, back pain, limb/muscle pain, or joint swelling, or any other problems, call your doctor right awayAsk your doctor when you can begin major physical activities again
EUFLEXXA offers various types of coverage to help meet your needs.
- 100% coverage on Medicare Part B* without restrictions
- ~50% of commercially insured patients pay a $0 copay1
- Coverage for patients with no insurance through the
EUFLEXXA Patient Direct Program
Not sure what type of coverage you have? Find out here
*Out-of-pocket cost may apply. Please check with your doctor.
EUFLEXXA has a wide-range of support including:
- The EUFLEXXA Commitment Program
- Educational materials to help you understand more about OA of the knee and your treatment
- Tools to help you find a doctor near you that can help treat your OA knee pain
- Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
- EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
- Altman R, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. Cartilage. 2019;10(1):43-52.
- Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskeletal Disorders. 2015;16:321.
- Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107.
- Nicholls M, et al. A comparison between rheological properties of intra-articular hyaluronic acid preparations and reported human synovial fluid. Adv Ther. 2018;35:523-530.
- Orthovisc [package insert]. Woburn, MA: Anika Therapeutics, Inc; 2005.
- Supartz [package insert]. Durham, NC: Bioventus LLC; 2012.
- Gelsyn-3 [package insert]. Durham, NC: Bioventus LLC; 2016.
- Hyalgan [package insert]. Parsippany, NJ: Fidia Pharma USA Inc; 2011.
- Genvisc-850 [package insert]. Doylestown, PA: OrthogenRx; 2016.
- Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.
- Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39(1):1-9.
- Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage. 2011;19(10):1169-1175.